PDCD1 and Merkel cell skin cancer: In 2019, four MCC patients with no response to anti-PD-1 monotherapy received a combination of panobinostat and anti-PD-1 therapy, and the results showed that HDACi may increase the effectiveness of anti-PD-1/PD-L1 therapy [92].